Certara, INC 10-Q quarterly reports

Certara, Inc. announced its Q2 2026 financial results, reporting a net loss from continuing operations and completing the sale of its medical writing business.

Certara, Inc. reported Q1 2026 results with a net loss, while also announcing the divestiture of its global medical writing business.

Certara, Inc. reported a 10% increase in total revenues for Q3 2025, reaching $104.6 million, and a significant rebound to net income of $1.5 million from a net loss in the prior year.

Certara, Inc. reported significant revenue increases and a return to net income for the first half of 2025, driven by robust demand and strategic acquisitions.

Certara's Q1 2025 shows a 10% revenue increase, fueled by strong performance in both its software and technology-enabled services segments.

Certara, Inc. announced its financial results for the third quarter of 2024, showing an 11% increase in total revenue compared to the same period last year.

Certara Inc. saw a 3% increase in total revenue for the second quarter of 2024, driven by a 13% rise in software revenue, while experiencing a net loss due to increased operating expenses.

Certara, Inc. saw a 7% increase in revenue in Q1 2024, but experienced a net loss due to higher operating and acquisition-related expenses.